Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study

Published:2020-02 Issue:2 Volume:2 Page:119-127
ISSN:2578-5745
Container-title:ACR Open Rheumatology
language:en
Short-container-title:ACR Open Rheuma

Author:

Pavelka Karel¹^ORCID,Kivitz Alan J.²,Dokoupilova Eva³,Blanco Ricardo⁴,Maradiaga Marco⁵,Tahir Hasan⁶,Wang Yi⁷,Porter Brian O.⁷,Stefanska Anna⁸,Richards Hanno B.⁹,Rohrer Susanne⁹,

Affiliation:

1. Charles University in Prague Czech Republic

2. Altoona Center for Clinical Research Duncansville Pennsylvania

3. Medical Plus s.r.o., Uherske Hradiste, and University of Veterinary and Pharmaceutical Sciences Brno Czech Republic

4. Hospital Universitario Marqués de Valdecilla Santander Spain

5. Centro de Investigación de Tratamientos Innovadores de Sinaloa Culiacán México

6. Barts Health National Health Service (NHS) Trust London UK

7. Novartis Pharmaceuticals Corporation East Hanover New Jersey

8. Novartis Ireland Limited Dublin Ireland

9. Novartis Pharma AG Basel Switzerland

Funder

Novartis

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr2.11102

Reference17 articles.

1. Spondyloarthritis

2. Emerging drugs for the treatment of axial and peripheral spondyloarthritis

3. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

4. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register

5. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four-week clinical trial

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment;Rheumatology;2024-08-12

2. Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis;Frontiers in Immunology;2024-07-15

3. Discovery of Small Molecule Interleukin 17A Inhibitors with Novel Binding Mode and Stoichiometry: Optimization of DNA-Encoded Chemical Library Hits to In Vivo Active Compounds;Journal of Medicinal Chemistry;2024-04-04

4. α-mangostin derivatives ameliorated mouse DSS-induced chronic colitis via regulating Th17/Treg balance;Molecular Immunology;2024-02

5. Achieving inactive disease in enthesitis-related arthritis with secukinumab following TNF-inhibitor failure;Rheumatology;2023-12-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3